Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 PTC Therapeutics Achieves $20M Roche Milestone | Contract Pharma

What are you searching for?

Sign in
Breaking News

PTC Therapeutics Achieves $20M Roche Milestone

Payment was triggered by the first commercial sale of Evrysdi in the U.S. which was approved by the FDA on August 7 to treat SMA.

By: Contract Pharma

Contract Pharma Staff

PTC Therapeutics, Inc. achieved a $20 million milestone payment from Roche under its license and collaboration agreement. The milestone payment was triggered by the first commercial sale of Evrysdi (risdiplam) in the U.S. Evrysdi was approved by the FDA on August 7, for the treatment of spinal muscular atrophy (SMA) in adults and children 2 months of age and older.
 
Evrysdi is a survival motor neuron 2 (SMN2)-directed RNA splicing modifier designed to treat SMA caused by mutations in chromosome 5q that lead to SMN protein deficiency. Evrysdi (risdiplam) is based on PTC science and is commercialized in the U.S. by Genentech, a member of the Roche Group. Roche led the clinical development of Evrysdi as part of a collaboration with the SMA Foundation and PTC Therapeutics.

“We are excited that Evrysdi is able to reach U.S. SMA patients so quickly following FDA approval,” said Stuart W. Peltz, Ph.D., Chief Executive Officer of PTC Therapeutics. “This is especially relevant during the COVID-19 global pandemic, given that Evrysdi can be delivered directly to patients at home.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters